🔗 Share this article

While the US continues making sweeping revisions to its vaccination guidelines, an unexpected name has surfaced somewhat surprisingly: Dr. Tracy Beth Høeg, an American of Danish descent sports medicine doctor and epidemiologist who rose to prominence by questioning COVID-19 vaccinations during the global health crisis and has concentrated on alleged deaths following Covid immunization in her short tenure at the FDA.

Proposed Changes to Childhood Immunization Program

Agency leaders planned to unveil radical changes to the childhood vaccine schedule earlier this month, bringing the US with the Danish vaccine program, it is understood – a substantial departure that would put the US at odds with many the international standard with no evidence for public health gain. The planned update has been postponed until the coming year.

Instead of the director of the vaccine center, Tracy Beth Høeg is listed to address the audience at the event. She was just designated acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to run the center this calendar year.

A Shift at the FDA

The acting appointment might represent a closer partnership between the drug and vaccine divisions as Høeg and Dr. Prasad strengthen their influence at the regulatory agency – and it suggests a renewed priority upon dismantling long-standing vaccines at the FDA.

Dr. Høeg has often pushed for discontinuing specific childhood vaccine recommendations in the US to become more like Denmark, a nation with nationalized medicine and a number of inhabitants approximately the population of Wisconsin’s.

So far comments, she has continued to focus on vaccines – typically the responsibility of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of medication approval.

Questions Over Expertise

The appointee has no apparent experience in medication creation, oversight or administrative roles, which has been standard for former directors of the CBER. She has served at the FDA as a top consultant to the FDA chief and the vaccine center since spring.

“She doesn’t seem to have the requisite experience” for running the CDER, remarked Jonathan Howard. “She has not conducted a scientific study. She is not versed in running a sizeable institution. She lacks background in pharmaceutical oversight.”

Former heads of the center would “understand laws and regulations and the underlying principles of pharmaceutical innovation”, noted Janet Woodcock. “Frankly, she lacks the kind of background that prior appointees who led CBER have had.”

The drug center has an enormous range of responsibilities at the agency, Woodcock emphasized.

“Many people just focuses on the new drug program, but the generic drug division authorizes thousands of generic medications. There’s a biosimilars program, over-the-counter program and so forth, and every single one must be managed,” Woodcock explained. “The area you overlook, that is the part that I always told people is going to bite you.”

Additionally, a major leadership aspect to the role, which supervises more than 5,000 employees. “It’s a enormous administrative position, if you perform it correctly,” she said.

Official Statement and Contentious Initiatives

Regarding concerns about Høeg’s fitness for the role and whether this appointment represents greater collaboration among regulatory chiefs on vaccines, a spokesperson responded that the “questions are based on flawed presumptions”.

“Her resume is consistent with the duties of her role,” the spokesperson said, citing the period Høeg spent counseling the FDA commissioner on “pharmaceutical safety and regulatory science, including computerized risk analysis and vaccine surveillance”.

In her interim role, Dr. Høeg takes over the commissioner’s controversial fast-track approval initiative, a controversial rapid medication authorization process that allegedly worried her predecessors. “How are these drugs being picked for this fast-track system? Who takes the calls?” Dr. Howard questioned. “There is a lot of secrecy happening at the agency right now.”

Broadly speaking, he said, “the Food and Drug Administration seems to be moving towards more relaxed regulations of pharmaceuticals, aside from shots.”

Documented Past Work on Immunizations

With immunizations, Høeg has a more documented, if concerning, past, some experts said. She published a analysis using non-validated volunteer-provided data to determine the frequency of heart inflammation following COVID-19 vaccination. She counseled the state of Florida surgeon general Joseph Ladapo, who reportedly have altered data to indicate Covid vaccinations are riskier than they are.

Included in her “desired changes” for the new federal leadership included changing rules for new vaccines and halting “non-essential” vaccines, she said following the vote on a podcast. At the agency, Høeg has reportedly proposed excluding adolescent males from receiving Covid vaccines.

“She’s an thorough true believer who begins with her conclusions and tailors the evidence to accommodate the science in a very misleading, untruthful manner,” Dr. Howard said.

Gaining Influence and a “Revenge Tour”

Høeg joined other dissenters, {like|